Table 3. Sub-arm analysis (n=47).

Arm, n (%)	PR, n (%)	SD, n (%)	PD, n (%)	ORR (CR+PR), n (%)	DCR (CR+PR+SD), n (%)
Arm A
Pathological examination
Adenocarcinoma (n=17)	2 (11.8)	7 (41.2)	8 (47.1)	2 (11.8)	9 (52.9)
Squamous carcinoma (n=7)	2 (28.6)	2 (28.6)	3 (42.9)	2 (28.6)△	4 (57.1)▽
Previous injection of paclitaxel
Yes (n=6)	2 (33.3)	1 (16.7)	3 (50.0)	2 (33.3)	3 (50.0)
No (n=18)	2 (11.1)	8 (44.4)	8 (44.4)	2 (11.1)#	10 (55.6)※
Arm AP
Pathological examination
Adenocarcinoma (n=14)	5 (35.7)	3 (21.4)	6 (42.9)	5 (35.7)	8 (57.1)
Squamous carcinoma (n=9)	1 (11.1)	4 (44.4)	4 (44.4)	1 (11.1)□	5 (55.6)◆
Previous injection of paclitaxel
Yes (n=6)	1 (16.7)	2 (33.3)	3 (50.0)	1 (16.7)	3 (50.0)
No (n=17)	5 (29.4)	5 (29.4)	7 (41.2)	5 (29.4)◻	10 (58.8)■

A sub-arm: ^△, ORR in squamous carcinoma and non-squamous carcinoma by Fisher’s exact test, P=0.552, no significant difference between the two arms; ^▽, DCR in squamous carcinoma and non-squamous carcinoma by Fisher’s exact test was P=1.000, no significant difference between the two arms; ^#, ORR with or without the application of paclitaxel by Fisher’s exact test was P=0.251, no significant difference between the two arms; ^※, DCR with or without the application of paclitaxel by Fisher’s exact test was P=1.000, no significant difference between the two arms; AP sub-arm: ^□, ORR in squamous carcinoma and non-squamous carcinoma by Fisher’s exact test, P=0.34, no significant difference between the two arms; ^◆, DCR in squamous carcinoma and non-squamous carcinoma by Fisher’s exact test was P=1.000, no significant difference between the two arms; ^◻, ORR with or without the application of paclitaxel by Fisher’s exact test was P=1.000, no significant difference between the two arms; ^■, DCR with or without the application of paclitaxel by Fisher’s exact test was P=1.000, no significant difference between the two arms. PR, partial response; SD, stable disease; PD, progressive disease; ORR, objective response rate; CR, complete response; DCR, disease control rate.